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Abstract    
We report the results of a prospective, randomized phase 3 trial evaluating the use of 
autologous peripheral blood stem cell transplantation (ASCT) vs. intensive 
consolidation chemotherapy in newly diagnosed AML patients in complete remission 
(CR1). Patients with AML between 16-60 yrs of age in CR1 after two cycles of 
intensive chemotherapy and not eligible for allogeneic SCT were randomized 
between intensive chemotherapy with etoposide and mitoxantrone or ASCT following 
high-dose cyclophosphamide and busulfan. Of patients randomized (chemotherapy 
n=259; ASCT n=258), more than 90% received their assigned treatment arm. The 
two groups were comparable as regards prognostic factors. The ASCT group showed 
a markedly reduced relapse rate (58% vs. 70%, p=0.02) and better relapse free 
survival (RFS) at five years (38% vs. 29%, p= 0.065, HR 0.82 (0.66-1.1) with non-
relapse mortality of 4% vs. 1% in the chemotherapy arm (p=0.02). Overall survival 
(OS) was similar (44% vs. 41% at 5 years, p=0.86) due to more opportunities for 
salvage with second-line chemotherapy and stem cell transplantation in patients 
relapsing on the chemotherapy arm. This large study shows a relapse advantage for 
ASCT as post remission therapy but similar survival since more relapsing patients on 
the chemotherapy arm were salvaged with a late transplantation for relapse. This trial 
is registered at http://www.trialregister.nl as NTR230 and NTR291. 
 
Introduction 
Autologous bone marrow transplantation (ABMT) following marrow ablative 
chemotherapy or radiotherapy has originally been developed as an alternative to 
allogeneic stem cell transplants for patients with acute myeloid leukemia (AML) with 
no suitable donor. Several randomized studies in patients with AML in first complete 
remission (CR1) subsequently suggested reduced relapse rates following ABMT.1-6 
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However, ABMT has been associated with prolonged marrow aplasia and with an 
excess of non-relapse mortality.2,3 As a result the relapse advantage of an 
autologous transplant was offset by enhanced toxicity and mortality which has 
precluded general acceptance of ABMT as post-remission treatment in AML.1-6 In 
addition these studies with marrow auto grafts were hampered by the fact that only a 
minority of the allocated patients, actually underwent the transplantation.7,8 
When hematopoietic growth factors provided the possibility to employ peripheral 
blood stem cells as the source of stem cells, autologous peripheral blood stem cell 
transplants (ASCT) offered the advantage of a markedly faster engraftment and 
accelerated hematological recovery as compared to marrow grafts.9-11 The switch to 
ASCT was also expected to enhance compliance to protocol treatment so that a 
greater fraction of patients assigned to ASCT would indeed receive their intended 
transplantation. However, critical prospective evaluations of ASCT have remained 
remarkably scarce, and were performed in series with relatively small numbers of 
patients.11,12 
Against this background, the Dutch-Belgian HOVON and Swiss SAKK leukemia 
cooperative groups set out to assess the clinical benefit of ASCT following high-dose 
cytotoxic therapy in a multicenter study in 517 patients with AML in CR1 following 
intensive anthracycline and cytarabine chemotherapy.13,14 ASCT was prospectively 
compared to intensive consolidation chemotherapy with etoposide and mitoxantrone 
which have been reported to exert potent anti-leukemic effects.13-15 
 
Materials and Methods 
Study Design and Chemotherapy 
Previously untreated patients with a confirmed diagnosis of AML were eligible for 
enrollment in the HOVON/SAKK AML-29 and AML-42 trials.13,15 The age range for 
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the HOVON/SAKK AML-29 trial was 16 to 60 years and for the AML-42 trial 18 to 60 
years. Patients with acute promyelocytic leukemia (APL) were eligible in the AML-29 
trial but they were not in the AML-42 trial. Patients with another active cancer were 
not eligible, nor were patients with severe heart, lung, or neurological disease 
(Supplementary Information). Patients in CR1 after cycle 2 received consolidation 
with a third cycle of chemotherapy with etoposide (100 mg/m2 on days 1 through 5) 
and mitoxantrone (10 mg/m2 on days 1 through 5) in case of favorable cytogenetics 
and early CR after cycle I. Unfavorable risk patients were planned for an allogeneic 
stem cell transplantation and could be randomized in the study in case an allogeneic 
transplantation was not feasible. Intermediate risk patients were candidates for an 
HLA matched allogeneic stem cell transplantation if a donor was available and the 
patient fulfilled the age criteria for an allograft in their center. If allogeneic stem cell 
transplantation appeared no realistic option, patients could be randomized between 
ASCT or the third cycle of chemotherapy with etoposide and mitoxantrone. 
Conditioning before ASCT consisted of high-dose chemotherapy with busulfan (4 
mg/kg orally days -4 through -7 and cyclophosphamide (60 mg/kg intravenously, 
days -2 and -3) followed by autologous peripheral blood stem cell re-infusion (see 
Supplementary Information). 
This was an investigator-sponsored study with no pharma company involvement. The 
study was approved by ethics committees of the participating institutions and was 
conducted in accordance with the Declaration of Helsinki. All patients gave their 
written informed consent. 
 
 
Prior Remission Induction Chemotherapy 
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Remission induction chemotherapy according the AML-29 and AML-42 protocols 
involved two cycles of combination chemotherapy.13,14 Cycle 1 consisted of 
cytarabine (200 mg/m2 on days 1 through 7) and idarubicin (12 mg/m2 on days 6, 7, 
and 8). Cycle 2 consisted of cytarabine (1000 mg/m2 every 12 hours on days 1 
through 6) and amsacrin (120 mg/m2 on days 4, 5, and 6). In the AML-42 protocol 
patients were also randomized between the aforementioned dose of cytarabine 
versus a more intensive cytarabine regimen (cycle 1 1000 mg/m2 on days 1 through 
5) and cycle 2 consisting of 2000 mg/m2 twice daily on days 1, 2, 4, 6) as 
described.13,14 In the AML-29 and part of the AML-42 trial patients were randomly 
assigned for induction to receive granulocyte colony stimulating factor (G-CSF) or no 
G-CSF during cycles 1 and 2 as described.13 
 
Criteria For Response and Endpoints   
CR, relapse and overall survival (OS) were previously defined.13,15 Relapse-free 
survival (RFS) refers to the interval from randomization to the date of death, or the 
date of relapse. Time to hematopoietic recovery was measured from the end of 
chemotherapy application both for patients treated according to chemotherapy cycle 
III or to the transplantation group to the time when the neutrophil and the platelet 
counts reached values of 0.5 x 109/l and 50 x 109/l, respectively.  
 
Statistical Methods 
Design and Randomization 
RFS was the primary endpoint. At the onset of this randomization in the AML-29 
study it was clear that the number of patients randomized between third 
chemotherapy course and ASCT would not be sufficient to answer the question with 
sufficient power. Therefore the randomization was planned to be continued in the 
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successive AML-42 study. Randomization was closed in 2006. After an additional 
follow up of 3.5 yrs 343 events (relapse or death in CR1) have been observed in both 
groups together. This number of events gives a power of 71% for the detection of a 
significant difference if the true hazard ratio of failure in the ASCT group compared 
with the chemotherapy group would be 0.76, which corresponds with an increase in 
the 5-year RFS from 30 to 50%.  
 Randomized assignments to study groups were balanced with the use of a biased-
coin minimization procedure as described (see Supplementary Information), 
 
Analysis 
All analyses were performed according to the intention-to-treat principle, irrespective 
of patients compliance with the protocol, but 12 ineligible patients randomized 
between cycle III (n=5) and ASCT (n=7) were excluded: patients with acute 
promyelocytic leukemia (n=6); never reached CR1 (n=2); relapsed before 
randomization (n=2); incorrect diagnosis (n=2).  
Cox regression analysis was used to estimate the effect of treatment group and 
covariates on RFS and OS (secondary endpoint). The possible heterogeneity of the 
treatment effects in subgroups was explored in post hoc analyses by estimation of 
the hazard ratios for each subgroup, together with 95% confidence intervals, and 
tests for interaction. A limited number of subgroup classifications were considered: 
cytogenetic risk category (favorable, intermediate, or unfavorable), age, WHO 
performance status (0, or 1 or 2), presence of extra-medullary disease and white 
blood cell count (≤ 20 x 109 /l) at diagnosis, and early (CR after cylce I) or late (CR 
after cycle II) CR1. P-values <0.05 were considered statistically significant, except for 
the tests for interaction with subgroups, where <0.01 was used because of multiple 
tests performed.  
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Results 
Between 1995 and 2006 2017 patients at diagnosis were enrolled in the AML-29 and 
AML-42 trial for remission induction treatment. After 2-courses of chemotherapy 
induction therapy, 76% of the patients were in CR1 (Table 1). The recommended 
choice of consolidation treatment in the protocol according to the cytogenetic risk 
stratification (see Methods) resulted in the randomization of 34% of patients while 
23% of patients went straight to consolidation chemotherapy (cycle III) and 27% were 
consolidated in CR1 with an allogeneic SCT depending on the availability of a HLA 
matched donor and clinical eligibility criteria (age, co-morbidity). Two percent of 
patients received an ASCT without randomization and 15% did not receive further 
therapy in CR1 due to early relapse or prolonged hypoplasia (Table I). Thus, of 517 
randomized patients 259 were assigned to consolidation chemotherapy cycle III and 
258 patients to ASCT. Median follow-up of patients alive is 106 months (range 13-
177). Nine patients in the chemotherapy group and 7 patients in the ASCT have been 
lost to follow-up between 1 and 12 years. The two treatment groups were matched 
with respect to age, cytogenetic risk, types of induction therapy (Table 2). Ninety-
three percent of the patients randomized to consolidation chemotherapy received the 
planned chemotherapy according protocol and 91% of the patients assigned to ASCT 
actually received the autologous transplant (Table 3).  
 
Outcome following chemotherapy or ASCT 
The ASCT treatment group showed a trend towards better RFS than the 
chemotherapy group (38% vs. 29% at 5 years, p=0.065, HR 0.82 (0.66-1.1) (Table 3; 
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Figure 1). In the ASCT group 156 patients had recurrence of AML, while 187 patients 
relapsed in the chemotherapy group, corresponding with an actuarial relapse rate at 
5 years of 58% and 70%, respectively (p=0.02, Table 3). Non-relapse mortalities (a 
measure of treatment-procedure related deaths) were estimated at 4% and 1% (at 5 
yrs) in the ASCT and chemotherapy groups (p=0.02). OS did not differ between both 
treatment arms (44% vs. 41%, p=0.86). Second line anti-leukemic treatment was 
applied to 116 (74%) of the 156 relapsing patients in the ASCT arm which involved 
ASCT (n=2, 1% of recurrences), allogeneic SCT (n=27, 17%) and chemotherapy 
(n=87, 55%). In contrast 150 of 187 (80%) relapsing patients in the chemotherapy 
group were treated in second line with ASCT (n=27, 14%), allogeneic SCT (n=47, 
25%) or chemotherapy (n=76, 40%). Thus a considerably greater proportion of 
patients following relapse in the consolidation chemotherapy group had the possibility 
for salvage with autologous or allogeneic stem cell transplantation (39% versus 
18%). Second complete remissions were attained in 27% of the relapsed patients in 
the ASCT group and 47% in the chemotherapy group resulting in long term survival 
of 7% and 15% for patients with relapse in the ASCT group and the chemotherapy 
group, respectively. 
 
Hematological Recovery And Treatment Related Toxicity  
A significantly enhanced recovery of peripheral blood granulocyte count was seen 
following ASCT as compared to consolidation chemotherapy (Figure 2). Thirty-two 
percent of ASCT patients reached neutrophil counts of >0.5 x 109/l at day 14 and 
88% on day 28 after transplant as compared to 1% and 42% respectively for patients 
consolidated with chemotherapy (p<.001). Platelet recovery demonstrated a biphasic 
pattern; in the first month after end of treatment the platelet recovery rate to >50 x 
109/l was slightly faster in the ASCT group (p=0.79). However, for the patients who 
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had not recovered by that time the platelet recovery proceeded at a slower rate in the 
ASCT group (p<.0001, fig 2) A similar pattern was seen with respect to time to 
platelet transfusion independency; the median time to transfusion independency was 
comparable between both groups, 24 days vs. 23 days, but after that the duration 
was longer in the ASCT group (p=0.003). In the ASCT group the incidences of grade 
3 and 4 bleedings and grade 3 and 4 infections were not different (see 
Supplementary Information S1). However, an increased incidence of fever of 
unknown origin (37% versus 21%, p<.001), gastro-intestinal (72% versus 29%, 
p<.001), hepatic (18% versus 6%, p<.001) and neurological (11% versus 4%, 
p=0.004) grade 2-4 adverse events were noted in the ASCT group.  
 
Prognostic Factors And Subgroup Analysis 
Table 4 shows the actuarial 5 year probabilities of RFS and OS and the hazard ratios 
in relation to clinical and hematological factors and according to treatment group.  
Increasing age was associated with a reduced RFS (P=0.01) and OS (P<0.001). 
Presence of extra-medullary disease at diagnosis also correlated with lower RFS 
(P=0.016) and OS (P=0.21). Cytogenetics showed particularly strong relationships 
with RFS and OS. The ASCT group showed better RFS than the chemotherapy 
group (at 5 yrs 38% vs. 29%), but this difference was not statically significant 
(p=0.065). However, if the patients of the monosomal karyotype with very poor RFS 
in both arms were excluded, the improvement in RFS for the ASCT arm was more 
pronounced (p=0.014). Patients attaining late CR (i.e. after induction cycle II) had a 
considerably lower RFS and OS (P<.001) than those in CR already after cycle I. 
In order to explore for a possible differential effect of ASCT treatment on outcome in 
any of the subgroups defined by the aforementioned factors, the effect of treatment 
was estimated separately by HR for RFS and OS with associated confidence 
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intervals combined with tests for interaction. In none of the latter analyses the test for 
interactions were significant (all P-values for these tests >0.10), including G-CSF 
priming and Ara-C dose applied. 
 
Discussion 
Randomized transplantation studies about ABMT in AML in CR1 had demonstrated 
reduced relapse rates in association with considerable procedural limitations 
including low treatment compliance, delayed hematological regeneration and 
increased non-relapse mortality.1-6 The present study demonstrates that these 
hurdles can largely be overcome. Autografts were successfully collected in a high 
number of patients and a high proportion of randomized patients did indeed receive 
their assigned treatment which enhanced the ability of evaluating the true value of 
ASCT according to intention to treat. The results show an advantage for ASCT as 
post-remission therapy in terms of relapse rate (57% versus 70% at 5 yrs, p=0,002) 
and with a higher RFS (39% versus 29% at 5 yrs, p=0,065). The OS was only slightly 
better after ASCT (44% vs. 41% at 5 yrs), but this difference was far from statistically 
significant (p=0.86). It should be noted that the similar OS value in the two groups 
was due to a higher proportion of successful salvage treatments, especially ASCT 
and allogeneic SCT, given after relapse in the chemotherapy group compared to the 
ASCT group. 
Despite a marked accelerated granulocyte recovery in the ASCT arm more side 
effects were noticed likely related to more intensive chemotherapy and resulting in a 
treatment related mortality of 4% in the ASCT arm vs. 1% in the chemotherapy arm. 
An important question is whether the choice of the remission induction therapy and 
the third cycle of mitoxantrone-etoposide for remission consolidation furnish a proper 
comparison as regards the value of ASCT. In the current study ASCT was given after 
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two cycles of induction therapy with cytarabine at conventional and intermediate dose 
levels and compared with the same treatment plus a third cycle of mitoxantrone-
etoposide. Does the latter treatment that served as a control represent a proper 
comparative reference? It has been thought for some time that  a consolidation 
treatment with high-dose cytarabine (HD-Ara-C) is optimal for young and middle aged 
adults with  acute myeloid leukemia.16 However, while an earlier study had shown 
superiority of 3000 mg/m2 over 400 mg/m2 cytarabine it did not furnish any direct 
evidence supporting the need of four cycles of HD-Ara-C16. Accumulating data 
suggest that multiple cycles of HD-Ara-C and dose levels of cytarabine above 1000 
mg/m2 whether applied in induction or consolidation are of limited value. In one 
randomized trial two postremission cycles of standard-dose Ara-C versus one HD-
Ara-C schedule made no difference. 17   In an additional study three HD-Ara-C cycles 
applied postremission did not yield better outcome than one cycle.18 A large recent 
Japanese study has recently reinforced the notion that standard dose levels of 
cytarabine applied as postremission therapy are not inferior to high dose levels.19  
Our group has previously employed and applied  in the standard arm of  the current 
study an intensive treatment program involving a first induction cycle of standard-
dose Ara-C, a second cycle of intermediate-dose Ara-C and one third final 
consolidation cycle, and we have reported outcome in a range similar to that after 
four cycles of HD-Ara-C. 13, 15, 20 
Our study does not allow a critical analysis of the value of ASCT in cytogenetically 
defined favorable risk and unfavorable risk subsets of AML patients because of the 
limited numbers of patients studied. However, the results are in line with other studies 
demonstrating no advantage of ASCT in patients with monosomal karyotype.17-19 
Excluding these patients from the analysis resulted in a significant advantage in RFS 
for the ASCT arm (p=0.01).  
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Irrespective of the choice of post-remission treatment, i.e. ASCT or chemotherapy, 
relapse of leukemia remains the predominant cause of treatment failure. This is 
reflected by the profound impact of karyotype subtype on RFS and OS. During the 
time span of the study, a number of insights have evolved as regards the therapeutic 
management of AML which may impact on the future enforcement of ASCT. For 
instance, within the cytogenetic defined intermediate risk group, subgroups are 
defined with favorable and unfavorable outcome based on somatic gene mutations in 
CCATT enhancer binding protein alpha (CEBPA), Nucleophosmin-1 (NPM1) and 
Fms-like tyrosine kinase 3 (FLT3).21-24 One study has already demonstrated that the 
subset of patients with NPM1+ mutations without FLT3-internal tandem duplications 
(FLT3-ITD) derive no survival benefit from allogeneic SCT.24 Direct outcome data as 
regards ASCT in these and other genotypes are currently not available but one might 
assume that the value of ASCT in these genotypic subsets will follow the cytogenetic 
prognostic analogies as has previously been demonstrated for allogeneic SCT.25 
Allogeneic transplantation following reduced dose-intensive conditioning is nowadays 
quite commonly used in patients with AML because of reduced early toxicities but it 
involves a greater relapse rate than myelo-ablative regimens.26-29 The ability of ASCT 
to suppress relapse in CR1 suggests that ASCT might also have merits in AML-CR1 
as a an adjunct regimen prior to allogeneic SCT. ASCT appears to minimize the 
leukemic burden and stabilize remissions and thus it might create better conditions 
and allow more time for graft versus-leukemia control. Finally, the remarkably low 
procedural mortality following ASCT that we report here after prolonged follow up, 
makes ASCT also potentially attractive for other subgroups, e.g. for favorable risk 
AML where it might contribute to preventing relapse.  
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Table 1. Treatment results of patients treated according HOVON-29 and 
HOVON-42 protocol 
               Cytogenetic risk group 
Favorable Intermediate Unfavorable/Very 
unfavorable  
Total 
Patients entered for induction n=233 n=1437 n=347 n=2017 
In CR after cycle II                             205 
(88%) 
1134 
(79%) 
193 
(56%) 
1532 
(76%) 
Not randomized 
  No consolidation        
  Consolidation  
      Chemotherapy cycle III    
      ASCT 
      Allogeneic SCT 
 
30 (15%)# 
 
116 (57%) 
3   ( 1%) 
17    (8%) 
 
166 (15%)# 
 
215 (19%) 
20  (2%) 
308 (27%) 
 
33 (17%)# 
 
22  (11%) 
1    (1%) 
84  (44%) 
 
229 (15%)# 
353 (23%) 
24   (2%) 
409 (27%) 
Randomized for consolidation 
    Chemotherapy cycle III 
    ASCT  
 
21 (10%) 
18   (9%) 
 
210 (19%) 
215 (19%) 
 
28  (15%) 
25  (13%) 
 
259 (17%) 
258 (17%) 
# remaining percentages refer to percentage of patients in CR after cycle II. 
Cytogenetic risk group: for details see legends Table 1. AML of favorable risk had 
core binding factor abnormalities: t(8;21) (q22;q22), inv(16)(p13.1;q22), or 
t(16;16)(p13.1;q22). The “very unfavorable” risk category had a monosomal 
karyotype as defined.30,31 The unfavorable risk AML’s were those without a 
monosomal karyotype or core-binding abnormalities, but with complex 
abnormalities15, t(6;9), t(11,19), t(9;22), 11q23.3q, inv(3),5q-,7q-, -5 or -7. AML 
without cytogenetic abnormalities or with loss of an X or Y chromosome as the only 
abnormality were classified as “normal cytogenetics” (“CN”) and AML with any other 
cytogenetic abnormalities were classified as “CA rest”. CN and CA-rest were 
considered as intermediate risk.
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Table 2. Patients with AML in complete remission randomized to consolidation 
with chemotherapy (cycle III ) or autologous stem cell transplantation (ASCT): 
demographics at diagnosis and preceding remission induction therapy 
Cycle III ASCT 
    
Total                        259 100% 258 100% 
    
Male sex                     126   49% 132   51% 
    
Age  (years)   
  Median                        47 yr  49 yr 
  16-40   98   38% 79   31% 
  41-50                        57   22% 60   23% 
  50-61                        104   40% 119   46% 
    
WBC at diagnosis [x10^9/l]   
  <=20                         138   53% 125   49% 
  20-100                       89   34% 96   37% 
  >100                         32   12% 36   14% 
    
FAB type    
  M0                           7     3% 12     5% 
  M1                           55   21% 64   25% 
  M2                           70   27% 62   24% 
  M4                           50   19% 60   23% 
  M5                           53   20% 46   18% 
  M6                           10     4% 6     2% 
  M7                           0   2     1% 
  RAEB                         3     1% 2     1% 
  RAEB-t  4     2% 3     1% 
  Unknown                      7     3% 1     0% 
    
Secondary leukemia            11     4% 18     7% 
Extra-medullary disease        37   14% 31   12% 
   
Cytogenetics          
Favorable   
  t(8;21)                      4     2% 5     2% 
  inv(16)                      17     7% 13     5% 
Intermediate                        195   70% 213   72% 
  CN-X-Y                       138   53% 145   56% 
  CA Rest                      67   26% 68   26% 
Unfavorable                     16     6% 16     6% 
Vey unfavorable (Monosomal karyotype)                          17     7% 11     4% 
   
  Not determined                     16     6% 16     6% 
   
Remission induction with  
G-CSF priming* 
  
  No                           195   75% 191   74% 
  Yes                          64   25% 67   26% 
   
Remission induction with cytarabine at *   
  Intermediate-dose level                 51   58% 45   54% 
  High-dose level                   37   42% 38   46% 
    
CR reached after #   
  Cycle  I   (early CR)                        210  81% 203   79% 
  Cycle II   (late CR)                       49   19% 55   21% 
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Third cycle of consolidation chemotherapy (cycle) vs. autologous stem cell 
transplantation (ASCT); WBC: white blood cell count; *as described in Methods 
remission induction therapy varied according to a randomized study for remission 
induction that compared two dose levels of cytarabine in remission induction and yes 
versus no G-CSF priming. #Achieved after 1 or 2 induction chemotherapy. 
Favourable: core binding factor abnormalities: t(8;21) (q22;q22), inv(16)(p13.1;q22), 
or t(16;16)(p13.1;q22). Unfavorable includes here the patients with an unfavorable 
karyotype and the patients with a monosomal karyotype. Intermediate: all other 
patients including those without cytogenetic abnormalities. 
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Table 3.   Outcome of patients with AML in first complete remission 
randomized to consolidation chemotherapy (cycle iii) or autologous stem cell 
transplantation (ASCT)  
Cycle III ASCT 
    
 Total  259 100% 258 100% 
    
Consolidation treatment    
 None  6     2% 11     4% 
 Chemo  240   93% 10     4% 
 ASCT  *  9     3% 236   91% 
 AlloSCT **  4     2% 1     0% 
    
Relapse-free survival (actuarial 5 years %)             P=0.065 
 Median [months]                11    14 
 RFS                          69   29% 89   38% 
 Relapse                      187   70% 156   58% 
 Death in CR1                 3     1% 13     4% 
    
Overall survival (actuarial 5 years %)                    P=0.86 
 Alive                        99   41% 101   44% 
 Dead                         160   59% 157   56% 
    
Cause of death 
 AML                          119   46% 114   44% 
 Pneumonitis                     8     3% 6     2% 
 Other infections                     12     5% 8     3% 
 Hemorrhage                      4     2% 4     2% 
 GvHD                         4     2% 4     2% 
 Secondary malignancy                      -   1     0% 
 Cardiac                     -   2     1% 
 Other                        13     5% 18     7% 
  
Numbers of patients (and %) per randomized treatment, i.e. consolidation cycle III or 
ASCT 
Chemo: chemotherapy; *ASCT: autologous stem cell transplantation; **AlloSCT: 
allogeneic SCT; RFS: relapse free survival; GvHD: graft versus host disease. 
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Table 4. Prognostic factors and test for interaction with treatment arm 
  
                  5 year RFS %  Cox regression RFS  B vs A   5 year OS % Cox regression OS  B vs A 
               Npat Event All A B HR  95%CI P-value Dead All A B HR  95% CI P-value 
               # # % % %       # % % %       
                
Total          517 359 33 29 38    317 42 41 44    
                 
Age              P=.010     P-int=.22  P<.001     P-int=.34 
 <=40          177 114 37 29 47 0.65 0.44-0.95 .025 89 52 47 57 0.85 0.56-1.30 .46 
 41-50         117 72 38 30 46 0.73 0.46-1.16 .18 68 43 39 48 0.82 0.51-1.33 .43 
 >50           223 173 28 29 27 0.98 0.73-1.32 .90 160 35 35 34 1.17 0.86-1.60 .33 
                 
Extra-medullary disease  P=.016     P-int=.25  P=.21     P-int=.85 
 No            449 304 35 31 39 0.87 0.69-1.08 .21 272 43 41 45 1.03 0.81-1.31 .79 
 Yes           68 55 22 16 28 0.61 0.36-1.05 .076 45 37 35 38 0.98 0.54-1.76 .93 
                 
Cytogenetics  P<.001     P-int=.13  P<.001     P-int=.20 
 Favorable     39 20 49 33 67 0.39 0.15-1.02 .055 11 72 71 72 1.03 0.31-3.36 .97 
 Intermediate  393 271 35 32 38 0.87 0.69-1.11 .27 244 43 40 45 1.00 0.78-1.28 .99 
 Unfavorable       25 20 20 18 21 0.77 0.32-1.86 .56  18 28 27 29 0.99 0.39-2.52 .99 
 Very unfavorable   28 28 0 0 0 1.76 0.82-3.78 .15 27 4 6 0 2.49 1.15-5.41 .021 
                 
CR reached after  P<.001     P-int=.35  P<.001     P-int=.29 
 Cycle I           413 275 37 32 42 0.78 0.61-0.99 .037 241 45 43 48 0.95 0.74-1.23 .72 
 Cycle II           104 84 20 18 21 0.97 0.63-1.49 .89 76 31 31 32 1.25 0.79-1.96 .34 
A: Chemo group, B: ASCT group; For cytogenetic risk classification: see Table 1. HR Hazard ratio estimate, CI confidence interval.  
P-values Cox regression: likelihood ratio test for difference between treatment groups within row-subgroup.  
The P-values in the “All” columns are for tests for trend or difference between the factor and RFS or OS 
The P-values for the test of interaction between the factor and treatment group are indicated by P-int. 
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Figure Legends 
 
Figure 1. 
Overall survival (OS) and relapse free survival (RFS) of patients with AML in first complete 
remission randomized to autologous stem cell transplantation (ASCT) or consolidation 
chemotherapy. 
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Figure 2.  
Recoveries of absolute neutrophil counts (ANC, 0.5 x 109/L) and platelet counts (50 x 109/L) 
following autologous stem cell transplantation or consolidation chemotherapy. Recovery was 
measured from the date of transplant in the ASCT group and for comparability from the last date of 
cycle III in the chemotherapy group. The calculations have been restricted to patients treated 
according to allocated treatment. 
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